STOCK TITAN
  1. Home
  2. News
  3. ACIU

Immunotherapy Pioneer Prof. Carl H. June Joins AC Immune’s Board of Directors

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
management

Prof. June is a world authority on immune tolerance and adoptive immunotherapy

Appointment reaffirms AC Immune’s scientific leadership in neurodegeneration

Stock ACIU logo
AC Immune SA

NASDAQ:ACIU

ACIU Rankings

#3637 Ranked by Market Cap
#2037 Ranked by Stock Gains
N/A Ranked by Dividends

ACIU Latest News

Mar 14, 2024
AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update
Feb 22, 2024
AC Immune Announces Upcoming Presentations at AD/PD™ 2024
Jan 22, 2024
AC Immune to Regain Global Rights to Crenezumab and Semorinemab
Jan 3, 2024
AC Immune Progress Update on Phase 2 Active Immunotherapy Clinical Pipeline for Alzheimer's and Parkinson diseases
Dec 15, 2023
AC Immune Announces Pricing of Underwritten Offering of Common Shares

ACIU Stock Data

Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Health Technology, Pharmaceuticals: Major, Manufacturing, Pharmaceutical Preparation Manufacturing
Switzerland
Lausanne

About ACIU

ac immune is a clinical-stage swiss-based biopharmaceutical company, listed on nasdaq, which aims to become a global leader in precision medicine for neurodegenerative diseases. the company designs, discovers and develops therapeutic as well as diagnostic products intended to prevent and modify diseases caused by misfolding proteins. ac immune’s two proprietary technology platforms create antibodies, small molecules and vaccines designed to address a broad spectrum of neurodegenerative indications, such as alzheimer’s disease (ad). the company’s pipeline features nine therapeutic and three diagnostic product candidates – with five product candidates currently in clinical trials. the most advanced of these is crenezumab, a humanized anti-amyloid-β monoclonal igg4 antibody that targets monomeric and aggregated forms of amyloid-β, with highest affinity for neurotoxic oligomers. crenezumab is currently in two phase 3 clinical studies for ad, under a global program conducted by the collabor